Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286354 | 1.00 | ALOX15 (0.33) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL12515514 | 1.00 | ALOX15 (0.33) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL31381002 | 0.81 | MEN1 (0.34) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL17012041 | 0.79 | CYP1A2 (0.39) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL13529680 | 0.78 | SMN1; SMN2 (0.40) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL1224326 | 0.78 | ALOX15 (0.34) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL1224399 | 0.78 | ALOX15 (0.34) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL1224327 | 0.78 | ALOX15 (0.34) | ALOX15RECQLL3MBTL1KDM4EMEN1 | |
| SCHEMBL13530882 | 0.76 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL14730545 | 0.75 | L3MBTL1 (0.35) | ALOX15RECQLL3MBTL1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912207-B2 | 2-aldoximino-5-fluoropyrimidine derivatives | Dow AgroSciences, LLP. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20110152300-A1 | 2-ALDOXIMINO-5-FLUOROPYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152300-A1 | 2-ALDOXIMINO-5-FLUOROPYRIMIDINE DERIVATIVES | AKR7A2, DPYD, DPM1 | ALOX15 2023/4885RECQL 1621/4885L3MBTL1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.